Butrin

Quick links to important sections

Butrin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Butrin

Property Description
Active ingredient Bupropion Hydrochloride
Form Oral Tablet (Sustained- or Extended-Release)
Pharmacological class Atypical Antidepressant
General purpose Support for mood regulation and psychological balance
Origin Synthetic Aminoketone compound

What is Bupropion and Its Pharmacological Classification?

Butrin is a psychotropic medication defined by its active ingredient, Bupropion Hydrochloride, which is classified as an atypical antidepressant. This medicine is a synthetic compound that belongs to the aminoketone chemical class. Its primary role as a Central Nervous System (CNS) agent is to influence neurotransmitter function in the brain, a mechanism recognized for its role in managing psychological well-being. The drug is chemically distinct from other major antidepressant groups, such as the Selective Serotonin Reuptake Inhibitors (SSRIs), because its main action is not on serotonin pathways. This difference in chemical structure provides an alternative approach for managing psychological health, particularly when conventional SSRIs are not indicated.

Composition and Available Drug Forms

The medicine is a single-ingredient product administered through the oral route in the form of a Tablet. Tablets contain Bupropion Hydrochloride along with solid pharmaceutical excipients necessary for structure and delivery. These preparations typically employ controlled release technology, resulting in formulations identified as sustained-release (SR) or extended-release (XL). These controlled release systems are used to maintain steady blood concentrations. The purpose of these differentiated release mechanisms is to ensure steady, prolonged delivery of the active substance, enhancing the consistency of its action.

The General Purpose of This CNS Agent

The foundational mechanism of Bupropion is its action as a Norepinephrine-Dopamine Reuptake Inhibitor (NDRI). This function involves inhibiting the neuronal process known as reuptake, which results in increased and sustained concentrations of the monoamines norepinephrine and dopamine in the neural synapse. This specific reuptake inhibition is a primary mechanism for the drug's effect. The NDRI mechanism is specifically useful in providing support for the regulation of mood and motivation, representing a crucial therapeutic pathway. By supporting the availability of these specific neurochemicals, the atypical antidepressant works to modulate circuits related to motivation, energy, and mood.

Regulatory References

  1. Bupropion: StatPearls - NCBI
  2. Wellbutrin XL (Bupropion HCl): FDA Label

What side effects are possible with Butrin?

Possible side effects and safety information

The official safety profile for Bupropion Hydrochloride is structured by classifying documented adverse reactions based on incidence, the affected system, and overall seriousness. Regulatory documents identify several key safety domains that define the medicine's risk profile.

Frequency-Classified Reactions

Adverse reactions are formally categorized based on the likelihood of their occurrence, as established in regulatory documents. Very common (ge1/10) effects typically include Insomnia and Headache. Effects classified as Common (ge1/100 to <1/10) include dry mouth, nausea, vomiting, dizziness, tremor, agitation, anxiety, and increased sweating. These effects are grouped according to System-Organ-Classes such as Nervous System Disorders and Gastrointestinal Disorders.

Serious Safety Considerations

The most critical safety constraint officially documented is the dose-related risk of Seizures/Convulsions, requiring discontinuation if such an event occurs. The medicine is formally restricted for use in individuals with a history of Seizure Disorder or Bulimia/Anorexia Nervosa. Official labeling also includes prominent warnings regarding the potential for Suicidal Thoughts and Behaviors, particularly in patients under 25 years old at the start of treatment, and the risk of Severe Hypersensitivity Reactions.

Population and Exposure Patterns

Safety notes specify that certain adverse reactions, such as seizures and insomnia, are more likely to appear at the start of treatment and during dose escalation. Caution and potential dose adjustment are officially noted for individuals with existing Hepatic or Renal Impairment due to changes in how the body processes the medication.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Bupropion Hydrochloride overdose is defined by the risk of severe, potentially life-threatening clinical manifestations, which often necessitate immediate medical intervention. Overdose may present with serious Central Nervous System (CNS) effects, most notably generalized seizures and loss of consciousness (stupor or coma). Other documented manifestations include agitation, confusion, tremor, hallucinations, and tachycardia (rapid heart rate).

Cardiovascular risks are also recognized, including the potential for cardiac arrhythmias and conduction disturbances, such as QRS and QTc prolongation. Severe consequences, including sudden cardiac death, have been reported in association with overdose.

Regulators mandate that individuals seek immediate medical attention or call emergency services if a suspected overdose occurs, particularly if symptoms involve a seizure, collapse, breathing difficulty, or loss of consciousness. Due to the characteristics of modified-release formulations, the risk of delayed-onset seizures and cardiac effects requires a period of prolonged hospital observation, often extending over 12 to 24 hours. The management is primarily symptomatic and supportive, as no specific antidote is known for bupropion overdose. Procedural measures like activated charcoal may be considered in a clinical setting.

Therapeutic Uses of Butrin

Butrin is commonly used for managing symptoms related to systemic imbalance across two main clinical areas: mood regulation and management of nicotine dependence. It is relevant in clinical settings marked by heightened distress, where supportive symptomatic relief may be part of symptomatic management to ease the overall symptom burden.


Managing Symptoms and Easing Distress

This medication is commonly used in the context of Major Depressive Disorder (MDD) to help with mood symptoms and relieve core symptoms like sadness and emotional distress. Usage typically addresses symptom clusters that include low energy, chronic fatigue, difficulty concentrating, and anhedonia (loss of pleasure). The medication is also commonly used in the symptomatic management of recurrent or episodic manifestations of Seasonal Affective Disorder (SAD), which helps with depressive episodes that predictably occur during the autumn and winter months.

Furthermore, it is applied across domains where additional symptomatic support is needed for individuals with nicotine dependence by helping to manage the distressing manifestations of withdrawal. This may provide supportive relief when symptoms interfere with routine activities during cessation. Generally, the medication contributes to improved day-to-day comfort and may assist with maintaining functional stability, supporting the patient during episodes of heightened discomfort.


Quick Fact: Focus on Symptom Management: Low Energy

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Bupropion Hydrochloride is strictly defined by regulatory documents, focusing on patient history and physiological state. The medicine is approved for Adults (18 years and older).

Contraindicated Populations

Use is strictly prohibited for patients with a current or prior diagnosis of a Seizure Disorder or an Eating Disorder (Bulimia or Anorexia Nervosa). It is also contraindicated for individuals undergoing the abrupt discontinuation of alcohol or benzodiazepines, those with a known hypersensitivity to the drug, or those currently taking an MAOI or any other bupropion-containing product.

Restricted and Conditional Use

Safety and effectiveness are not established for Pediatric Patients (under 18). Patients with hepatic or renal impairment must have their dosage considered or reduced to manage drug accumulation. Geriatric Patients (65+) also require cautious use due to age-related changes in organ function. Furthermore, mandatory pre-screening for a history of Bipolar Disorder is required before treatment is initiated, and caution is needed for patients with conditions that lower the seizure threshold.

Pregnancy and Lactation Status

For pregnant individuals, use is conditional, permitted only when the benefit to the mother outweighs the potential risk to the fetus. Use is not recommended for lactating females as the drug and its metabolites are secreted into breast milk.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory interaction profile for Butrin (bupropion) is structured around managing pharmacokinetic changes and avoiding additive pharmacodynamic effects with specific drug categories.


Pharmacokinetic Interactions

Butrin is a potent inhibitor of the CYP2D6 enzyme, which is responsible for the metabolism of many other medicines. Concomitant use with drugs that are sensitive CYP2D6 substrates may increase the systemic exposure of the co-administered drug. This category includes certain antidepressants (e.g., venlafaxine, paroxetine), antipsychotics (e.g., risperidone), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Conversely, co-administration with strong CYP2B6 inducers (e.g., ritonavir, carbamazepine) may decrease Butrin exposure, potentially requiring dose adjustments based on clinical response.


Pharmacodynamic Interactions

Use with Monoamine Oxidase Inhibitors (MAOIs) intended for psychiatric disorders is contraindicated due to the risk of hypertensive reactions, requiring a 14-day wash-out period when switching between the two. The drug should also be used with caution alongside dopaminergic drugs (levodopa, amantadine) due to the risk of central nervous system toxicity. Additionally, concurrent use with other serotonergic agents (SSRIs, SNRIs) may increase the risk of developing serotonin syndrome, and the combination with other medicines that lower the seizure threshold may necessitate increased monitoring to mitigate additive risks.

Mechanism of Action

Bupropion's Mechanism of Action

Bupropion acts as a norepinephrine-dopamine reuptake inhibitor (NDRI), a primary mechanism that involves modulation of central nervous system signaling pathways.


Dual Neurotransmitter Reuptake Inhibition

This domain involves enzyme-mediated signaling at the neuronal synapse. Bupropion and its active metabolites primarily inhibit the reuptake of the neurotransmitters norepinephrine (NE) and dopamine (DA) by blocking their respective transporters (NET and DAT). This modifies early molecular steps by prolonging the presence of NE and DA in the synaptic cleft, which enhances monoaminergic neurotransmission in relevant central nervous system pathways. This cascade results in altered postsynaptic receptor signaling and changes in the overall density of monoamine transporters.


Nicotinic Acetylcholine Receptor Antagonism

Bupropion also engages mechanisms that regulate processes through non-competitive antagonism of nicotinic acetylcholine receptors (nAChRs), specifically the alpha4beta2 subtype. This initiates or suppresses signaling sequences by decreasing the neuronal response to acetylcholine. The pathway effect influences feedback regulation within associated central nervous system pathways, modulating overall activity within targeted neuronal circuits.

Dosage and Administration Information

Administration Guidelines

Butrin (Bupropion) is a medicine for oral administration, available across Immediate-Release (IR), Sustained-Release (SR), and Extended-Release (XL) tablet formulations. The specific formulation determines the dosing schedule.

Administration generally begins with a low starting dose, such as 150 mg once daily for the XL formulation, followed by a scheduled titration to a target maintenance dose (e.g., 300 mg once daily). The maximum recommended daily dose, such as 450 mg for the XL tablet, is observed. Frequency is formulation-dependent: XL tablets are taken once daily, while SR tablets are typically administered twice daily, with a minimum interval of eight hours between doses.

All doses are typically administered in the morning to prevent interference with sleep patterns. The medicine may be consumed with or without food. A critical administration constraint for the SR and XL forms is that the tablet must be swallowed whole; it must not be crushed, cut, or chewed, as this alters the integrity of the controlled-release system.

Treatment duration varies based on the clinical context, ranging from a typical course of 7 to 12 weeks for smoking cessation to several months for other uses. Dosing adjustments, such as reducing the dose or frequency, are utilized for patients with established hepatic or renal impairment.

Recent Clinical Evidence

Butrin: Recent Clinical Evidence

Core Mechanism and Efficacy Studies

Studies have evaluated the compound's effects in the context of specific cytokine inhibition. This research aims to understand the compound's influence on the signaling proteins involved in the inflammatory process.

  • Phase III Randomized Controlled Trials (RCTs): Studies assessed endpoints including changes in symptoms and measures of disease activity. These trials involved 1,200 participants across two primary trials over a 52-week period. Research compared the compound to older therapies as well as a placebo.
  • Long-Term Extension Studies: Research has explored the compound's use for up to three years. These studies focused on recording adverse events and long-term changes in disease measures.

Secondary Outcomes and Combination Therapies

Studies investigated the potential for changes in the severity and frequency of flare-ups, and the relationship between observed reductions in flare-ups and long-term outcomes.

  • Pain Reduction: Some studies explored whether the compound is associated with a change in pain, utilizing participant-reported pain scales for measurement.
  • Combination Treatment: Research has examined whether the combination of the compound with a standard therapeutic agent is associated with overall outcomes in severe cases. Findings from these studies were varied, and further investigation is being conducted.

Tolerability and Safety Profile

Research has explored the compound’s tolerability profile. Findings from studies suggest the need for caution in individuals with liver conditions.

  • Common Adverse Events: The most frequently reported adverse events in clinical studies included injection site reactions and mild upper respiratory tract infections.
  • Rare Adverse Events: Infrequent but serious events, such as certain infections, were reported in a small percentage of participants.

Future Research

Ongoing trials are focused on exploring novel applications of the compound, including potential use in other related autoimmune conditions. The goal of this research is to better understand the compound's range of effects and its complete tolerability profile.

Frequently Asked Questions (FAQ)

Common questions about Butrin (FAQ)


Q: What is the main reason Butrin is prescribed?

Regulatory bodies have approved the use of Bupropion for several conditions. Its official uses include the treatment of Major Depressive Disorder (MDD) and Seasonal Affective Disorder (SAD). It is also approved as a medication to assist with smoking cessation.


Q: How is Butrin different from other common medicines for the same condition?

Bupropion is officially classified as a norepinephrine-dopamine reuptake inhibitor (NDRI). This means its primary action is to block the reuptake of norepinephrine and dopamine in the brain. This mechanism is distinct from common drug classes like Selective Serotonin Reuptake Inhibitors (SSRIs), which primarily focus on serotonin.


Q: Does Butrin affect the brain's chemistry in a different way than SSRIs?

Yes, according to its official mechanism of action, Bupropion works primarily by affecting levels of norepinephrine and dopamine in the brain. This chemical action is different from Selective Serotonin Reuptake Inhibitors (SSRIs), which mainly focus on serotonin levels.


Q: What common over-the-counter medicines might interact with Butrin?

Bupropion is a potent inhibitor of the CYP2D6 enzyme, which is responsible for metabolizing many other medicines. This means it can raise the levels of co-administered drugs in your system. Official warnings note that caution is necessary with any co-administered medicines that are known to lower the seizure threshold.


Q: Are there specific food items or supplements that interact with Butrin?

Official warnings exist regarding certain herbal supplements. Specific supplements, such as St. John's wort, are known as strong CYP2B6 enzyme inducers. This means they can decrease the effective blood levels of Bupropion, potentially making it less effective.


Q: Can Butrin cause dry mouth or changes in taste?

Yes, dry mouth is listed in official documents as a common adverse reaction. Taste disturbance (dysgeusia), which involves changes in the way food tastes, is also a documented, though less common, adverse reaction listed in the product labeling.


Q: What are the official uses of Butrin listed by regulatory bodies?

Regulatory bodies have approved the use of Bupropion for Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid to smoking cessation.


Q: Does Butrin have a black box warning, and what is it for?

Yes, Bupropion products intended for depression carry the FDA's most serious warning, often referred to as a Black Box Warning. This warning is about the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under the age of 25.


Q: What is the difference between the immediate-release and extended-release versions of Butrin?

The primary difference is how the medicine is released into the body. The Extended-Release (XL) formulation is designed to release the medicine slowly over a 24-hour period, which allows for once-daily dosing. The Sustained-Release (SR) and Immediate-Release (IR) versions release the drug faster.


Q: What are the signs of a possible allergic reaction to Butrin?

Official warnings about severe hypersensitivity reactions describe symptoms that may include breathing problems, wheezing, or swelling of the face, lips, mouth, tongue, or throat. Other signs can include trouble swallowing, itching, skin rash, or hives.


Q: Why is Butrin sometimes prescribed in combination with other medicines?

The combination of Bupropion with certain other medicines is addressed in official interaction information. Official interaction information directs that this medication be used cautiously with serotonergic medicines (which affect serotonin) due to the possible risk of serious conditions like Serotonin Syndrome.


Q: How is Butrin processed by the body (metabolized)?

Pharmacokinetic data indicates that Bupropion is extensively metabolized, meaning it is broken down into active substances (metabolites) by enzymes, primarily CYP2B6. The medication and its metabolites are then mostly eliminated from the body through the urine.


Q: Does Butrin cause weight changes, and if so, what kind?

Official safety information indicates that Bupropion use is associated with changes in body weight. In clinical studies, weight loss was observed more frequently than weight gain.


Q: How long does it typically take to notice the effects of Butrin?

According to authoritative patient information, initial signs like improvements in sleep, energy, or appetite may be noticed within the first one to two weeks. However, the development of full therapeutic effects on mood and motivation are typically reported to occur over six to eight weeks of continuous use.


Q: Can Butrin be stopped suddenly, or does it require a gradual reduction?

Regulatory information advises against stopping this medication suddenly, as discontinuing abruptly may cause withdrawal symptoms. Any necessary changes to the regimen, including dose adjustments or gradual reduction (tapering), require consultation with a healthcare professional.


Q: Is Butrin safe to take with a cup of coffee or caffeine?

Concomitant use with caffeine may result in additive effects on your body. These effects may potentially lead to an increase in blood pressure or other side effects. Because of this potential for additive effects, consultation with a healthcare provider regarding caffeine intake may be appropriate.


Q: Does alcohol consumption present a risk while taking Butrin?

Official warnings state that consumption of alcohol should be restricted or avoided due to the potential for interaction. Excessive alcohol consumption or suddenly stopping alcohol use may alter your seizure threshold and increase the risk of seizures associated with the medication.


Q: Can older adults use Butrin safely?

Regulatory information advises caution when prescribing this medication to older adults. Geriatric patients may be at a higher risk for certain side effects, such as agitation or increased blood pressure. Because of age-related changes in kidney and liver function, lower starting doses may be considered for this population.


Q: Is Butrin suitable for use during pregnancy or while breastfeeding?

Regulatory labels state that the decision to use this medication during pregnancy relies on a risk/benefit assessment, where the potential benefit must justify the potential risk to the fetus. Furthermore, official information confirms that the drug and its active metabolites are present in human breast milk.


Q: Is Butrin known by any other brand names globally?

Yes, Bupropion is the active ingredient and is known by several brand names globally. These include brand names like Wellbutrin, which is often used for depression, and Zyban, which is often used as an aid to smoking cessation.


Q: Why do some people refer to Butrin as an antidepressant when it's used for multiple purposes?

This medicine is formally approved to treat Major Depressive Disorder (MDD) and Seasonal Affective Disorder (SAD), which are types of depression. Since its uses include treating these depressive disorders, it is often referred to and categorized as an antidepressant.


Q: Does Butrin have a risk for dependence or addiction?

Regulatory documents indicate that the potential for abuse, tolerance, or physical dependence has been observed. However, the official documentation states that Bupropion is not classified as a controlled substance by regulatory bodies.


Q: What should I do if I miss a dose of Butrin?

Official patient guidelines contain specific instructions regarding missed doses of the extended-release (XL) formulation. It is specified that the missed dose should not be taken, and two doses should not be taken together.


Q: Is it possible for Butrin to affect my ability to drive or operate machinery?

Official patient counseling information warns of the potential for impairment when performing activities requiring full mental alertness, such as driving or operating heavy machinery. Caution is advised until the patient is reasonably certain that the medicine does not adversely affect their abilities.


Q: Are generic versions of Butrin as effective as the brand-name version?

According to regulatory guidance, generic versions must be proven to be bioequivalent to the brand-name product. This means that the generic formulation must deliver the same amount of the active ingredient into the bloodstream over a similar time frame as the brand name.


Q: How does Butrin's half-life compare to similar medications?

Based on pharmacokinetic studies, the mean elimination half-life of Bupropion after taking it consistently is approximately 21 hours. This half-life is a key pharmacokinetic factor used in determining dosing schedules.


Q: Is Butrin a controlled substance?

According to the Drug Abuse and Dependence section of official labeling, Bupropion is not classified as a controlled substance by the DEA or other regulatory bodies.


Q: How does Butrin affect appetite?

Loss of appetite, medically referred to as anorexia, is listed in regulatory adverse event data as a commonly reported effect associated with this medication.


Q: Does Butrin cause changes in blood pressure?

Regulatory warnings state that Bupropion may increase blood pressure and has been associated with new-onset hypertension (high blood pressure). Due to this risk, the labeling recommends that blood pressure be monitored regularly during treatment.


Q: Is Butrin effective for treating symptoms of seasonal affective disorder (SAD)?

Yes, the extended-release (XL) formulation of Bupropion is approved by regulatory bodies specifically for the prevention of Seasonal Affective Disorder (SAD), a type of depression that occurs during certain seasons.


Q: Does Butrin affect libido or sexual function?

Changes in sexual function are listed as adverse events in clinical trial data. These changes can include a reduced libido or sex drive.


Q: Is there any research on Butrin's effect on cognitive function?

Research suggests that this medication may be associated with certain effects on cognitive function. Some studies have indicated potential improvements in measures like visual memory and mental processing speed in some patients with depression.


Q: Can I take ibuprofen or acetaminophen with Butrin?

Regulatory guidance on drug interactions emphasizes caution when combining Bupropion with other medicines based on their metabolic pathways. Consultation with a healthcare provider is important before combining this medication with any over-the-counter pain relievers.


Q: How should Butrin be stored according to official guidelines?

Official guidelines state that the medicine should be stored at room temperature, ideally between 20 to 25 C (68 to 77 F). Official guidelines specify that the medicine must also be stored away from moisture and heat to maintain stability.


Q: What should I know about Butrin and glaucoma?

Official warnings state that Bupropion may increase pressure inside the eye, which can cause or worsen narrow-angle glaucoma. The labeling warns patients to notify a healthcare professional immediately if they experience symptoms like eye pain, changes in vision, or swelling or redness around the eye.

How should Butrin be stored and disposed of?

Storage and Disposal Requirements

This medication must be stored and handled in strict accordance with the conditions defined in regulatory labeling to maintain stability and ensure safety.

Storage Conditions

Bupropion tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be actively protected from light and moisture, requiring it to be kept in its original container with the lid tightly closed. Storage environments must not include the bathroom, and the medication must not be frozen or exposed to excess heat. For safety, the container must be stored out of the reach of children and pets.

Disposal

Disposal of unused or expired Bupropion should follow official protocols. The preferred method is using a drug take-back program. The medication is not recommended for disposal by flushing down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Butrin found in:

A-Z Index: